title: Expression of CD44v6 and integrin-β1 for the prognosis evaluation of pancreatic cancer patients after cryosurgery.
abstract: BACKGROUND
  Many previous studies demonstrated that cell adhesion molecules CD44v6 and integrin-β1 had been extensively investigated as potential prognostic markers of various cancers. However, data in PC are scarce.
  
  
  METHODS
  We now investigate CD44v6 and integrin-β1 mRNA expression in PBMC by a triplex real-time RT-PCR assay and protein expression in plasma by ELISA. All specimens were collected from 54 PC patients who received the treatment of cryosurgery as well as 20 healthy individuals (control).
  
  
  RESULTS
  The mRNA and protein expression levels of CD44v6 and integrin-β1 in patients were significantly increased compared with control group (P<0.05). The high CD44v6 mRNA and protein expression were significantly correlated with clinical stage, tumor differentiation, LNM, liver metastasis and decreased median DFS (P<0.05), while the high integrin-β1 mRNA and protein expression were significantly correlated with clinical stage, LNM, liver metastasis and decreased median DFS (P<0.05). Clinical stage, LNM, liver metastasis, CD44v6 mRNA and protein expression were the independent predictors of survival in PC patients (P<0.05). Moreover, CD44v6 and integrin-β1 mRNA and protein expression levels were significantly decreased in patients in 3 months after cryosurgery (P<0.05). No significant difference was found in CD44v6 mRNA and protein expression between patients in 3 months after cryosurgery and control group (P>0.05).
  
  
  CONCLUSIONS
  CD44v6 and integrin-β1 mRNA and protein expression in blood may serve as biomarkers for the development and metastasis of PC, and as prognostic indicators for PC. They may become useful predictors in assessing outcome of PC patients after cryosurgery.
  The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/4035308681009006.
authors.affiliation: Department of Oncology, The GIBH Affiliated Fuda Hospital, Chinese Academy of Sciences, Guangzhou 510305, China. xukc@vip.163.com.
authors.forename: Gang
authors.initials: G
authors.lastname: Zhou
authors.forename: David
authors.initials: D
authors.lastname: Chiu
authors.forename: Dajiang
authors.initials: D
authors.lastname: Qin
authors.forename: Lizhi
authors.initials: L
authors.lastname: Niu
authors.forename: Jinlei
authors.initials: J
authors.lastname: Cai
authors.forename: Lihua
authors.initials: L
authors.lastname: He
authors.forename: Dongfeng
authors.initials: D
authors.lastname: Tan
authors.forename: Kecheng
authors.initials: K
authors.lastname: Xu
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D016022:Case-Control Studies; D002454:Cell Differentiation; D003452:Cryosurgery; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000097:blood* / Q000235:genetics; D019012:Integrin beta1 / Q000097:blood* / Q000235:genetics; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000276:immunology / Q000556:secondary; D008297:Male; D008875:Middle Aged; D060885:Multiplex Polymerase Chain Reaction; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D012333:RNA, Messenger / Q000097:blood; D060888:Real-Time Polymerase Chain Reaction; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C112697:CD44v6 antigen; D018960:Hyaluronan Receptors; D019012:Integrin beta1; D012333:RNA, Messenger